LiliumX
Southall, United Kingdom
Bispecific antibodies are the next breakthrough in cancer therapy, but current R&D is limited by a lack of scalable and flexible design platforms. LiliumX overcomes this limitation by using a modular protein platform, rapidly generating and testing thousands of candidate bispecifics using robotic screening and big data analysis to discover bispecific lead assets with entirely new modes of action.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2020
- Website
- www.valinktx.com/
Categories
Disease Areas
Technologies
Only accessible to MedStartr community members.
Join nowWhat do you think of LiliumX?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now